Prevalence of Gallstones in Patients with Chronic Myelocytic Leukemia

Basit Öğe Kaydı
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridKarincaoglu, Melih/0000-0002-9727-5128
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.contributor.authorAtes, Fehmi
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorKarincaoglu, Melih
dc.contributor.authorAladag, Murat
dc.contributor.authorAydogdu, Ismet
dc.date.accessioned2024-08-04T20:31:10Z
dc.date.available2024-08-04T20:31:10Z
dc.date.issued2009
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: The aim of the present case-control study was to determine whether or not the prevalence of gallbladder stones (GBS) was increased in patients with chronic myelocytic leukemia (CML) and to investigate clinical and laboratory characteristics of CML patients with GBS. Subjects and Methods: This study included 56 patients with CML and 55 sex- and age-matched healthy controls. All participants underwent abdominal ultrasonography and the main clinical and laboratory characteristics were recorded. Results: Gallbladder stones were detected in 13 (23.6%) patients with CML and in 3 (5.4%) control individuals (p < 0.05). The mean follow-up period of CML patients after diagnosis was 54.6 months, range 3-120 months. Hemoglobin levels were higher in the control group than in CML patients. However, total bilirubin, unconjugated bilirubin, lactate dehydrogenase levels, leukocyte and thrombocyte counts, frequency of splenomegaly and hepatomegaly were higher in the CML than in the control group (p < 0.05). Other clinical and laboratory values were not significantly different between the groups. CML patients with and without GBS were also compared for clinical and laboratory values. Age and follow-up period of CML patients after diagnosis were higher in the CML patients with GBS (p < 0.05). Conclusions: Higher prevalence of GBS in CML patients than in healthy controls was detected. We suggest that CML may increase the frequency of GBS, apart from other well-known risk factors. This risk is probably related to increased unconjugated bilirubin, which determines hemolysis, older age and long follow-up period of CML patients after diagnosis. Copyright (C) 2009 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000204346
dc.identifier.endpage179en_US
dc.identifier.issn1011-7571
dc.identifier.issue3en_US
dc.identifier.pmid19349718en_US
dc.identifier.scopus2-s2.0-64349107427en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage175en_US
dc.identifier.urihttps://doi.org/10.1159/000204346
dc.identifier.urihttps://hdl.handle.net/11616/94782
dc.identifier.volume18en_US
dc.identifier.wosWOS:000265114700003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofMedical Principles and Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic myelocytic leukemiaen_US
dc.subjectGallbladder stonesen_US
dc.subjectHemolysisen_US
dc.titlePrevalence of Gallstones in Patients with Chronic Myelocytic Leukemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu